Skip to content

Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease

Developing Novel Non-invasive Electrophysiological Biomarkers of Dysfunction in Spinal and Cortical Pathways and Sensorimotor Impairments in Motor Neurone Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06320444
Enrollment
240
Registered
2024-03-20
Start date
2023-06-15
Completion date
2025-07-15
Last updated
2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Motor Neuron Disease Progressive Spinal Muscle Atrophy, Multiple Sclerosis, Postpoliomyelitis Syndrome, Primary Lateral Sclerosis

Keywords

Electroencephalography (EEG), Peripheral Nerve Stimulation, Vibration-Induced Stimulation, Neurodegeneration, Electrophysiology, Biomarkers, Neuromuscular Physiology, Spinal Connectivity

Brief summary

Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS). This variability requires biomarkers that accurately classify and reliably track clinical subtypes as the disease progresses. Degeneration occurs in the brain and spinal cord, however, non-invasive diagnosis of spinal cord function remains highly challenging due to its unique alignment in spine. Disruption of complex spinal and cortical circuits that transmit and process neural signals for position sense and movement has not been adequately captured in the neurophysiological profiling of ALS patients. The overarching aim of this study is to reveal and quantify the extent of change in the sensorimotor integration and its potential contribution to network disruption in ALS.

Detailed description

Background: Substantial variability exists in the onset, and rate of degeneration across individuals with Motor Neurone Disease (MND) or Amyotrophic Lateral Sclerosis (ALS). This variability requires biomarkers that accurately classify and reliably track clinical subtypes as the disease progresses. Degeneration occurs in the brain and spinal cord, however, non-invasive diagnosis of spinal cord function remains highly challenging due its unique alignment in the spine. Disruption of complex spinal and cortical circuits that transmit and process neural signals for position sense and movement has not been adequately captured in the neurophysiological profiling of ALS patients. Aim: To develop, test, and employ non-invasive techniques to explore (dys)function between motor, sensory brain, and spinal networks in ALS. The project will address if the electrical activity of the cortical-spinal network by the of use peripheral stimulation (vibration, electrical nerve stimulation) to probe and reveal the normal or abnormal communication between brain and spinal networks. It is expected to reveal novel neurophysiological signatures in ALS patients compared to healthy controls. Study Design & Data Analysis: Surface electrodes will be mounted over the targeted regions in conjunction with High-Density EEG and High-density Electromyography (EMG). A physical and mathematical model of the underlying sources of electric activity (source localization) will be carried out at rest, during task, and with non-invasive peripheral nerve stimulation (PNS) and TMS. A separate paradigm will augment sensorimotor communication between the primary motor cortex (M1) and the somatosensory cortex (S1). Mild vibration (5N/\< 500 grams) will be applied to the wrist and/or bicep tendon transcutaneously. Vibration in conjunction with non-invasive peripheral nerve stimulation will induce transient changes (30 seconds maximum) in the intrinsic excitability of motor neurons in the spinal cord. Surface EMG will capture altered MN activity at the spinal level and the anticipated augmented communication in cortical networks (S1-M1) will be captured with EEG through connectivity analysis. Non-invasive transcranial magnetic stimulation in conjunction with vibration/nerve stimulation will be recorded to explore upper motor neurone influences on the altered intrinsic excitability of spinal motor neurons. Data collection: EXG-EEG-EMG and TMS/Peripheral Stimulation recordings will be conducted using a BioSemi® ActiveTwo system with 128 active sintered Ag-AgCl electrodes and headcaps (BioSemi B.V., Amsterdam, The Netherlands). The TMS system is a Brainbox DuoMAG (Brainbox Ltd., Cardif, Wales, UK) which can be used with a Digitimer peripheral stimulator.

Interventions

PROCEDURE232 Electrode Electrophysiology (EEG-ECG-EMG-EXG)

Noninvasive 232 Channel Electrode Electrophysiological signals (EEG-ECG-EMG-EXG) will be recorded from electrodes placed in a montage over the scalp, neck,and upper back along with muscles located on the hand. These signals will be recorded while resting or performing voluntary task. Other Intervention: The 232 electrode noninvasive electrophysiological data will be recorded in response to non-invasive peripheral nerve stimulation or vibration induced stimulation. These sessions are designed to engage specific cortical motor networks of interest for evaluating sensorimotor networks. (Cognitive, behavioural, motor, spinal, and sensory)

Sponsors

Motor Neurone Disease Association, UK
CollaboratorUNKNOWN
Irish Research Council, IE
CollaboratorUNKNOWN
Health Research Board, IE
CollaboratorUNKNOWN
Research Motor Neurone, IE
CollaboratorUNKNOWN
Thierry Latran Foundation, FR
CollaboratorUNKNOWN
ALS Association, USA
CollaboratorUNKNOWN
University of Dublin, Trinity College
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\- Healthy Volunteers: * age and gender matched to patient groups * intact physical ability to take part in the experiment. Patients: * Diagnosis of ALS, PLS, PMA, SMA, Polio or MS * capable of providing informed consent.

Exclusion criteria

\- Healthy Controls: * History of neuromuscular * neurological or active psychiatric disease disease * history of reaction or allergy to recording environments, equipment and the recording gels. Patients: * presence of active psychiatric disease * any medical condition associated with severe neuropathy (e.g. poorly controlled diabetes). * History of reaction or allergy to recording environments, equipment and the recording gels.

Design outcomes

Primary

MeasureTime frameDescription
Biomarker of sensorimotor integrationBaseline to 2-years after baselineA viable biomarker of sensorimotor integration for reliable and early distinction between healthy people and Motor Neuron Disease patient sub-phenotypes. This will be achieved by comparing connectivity measures between EEG, Non-cortical CNS, and EMG electrophysiological signals. The integration will also be seen in spectral analysis measures.
Determination of the feasibility of sensorimotor signatures as reliable biomarkers of ALSBaselineThe sensorimotor integration and signature biomarkers achieved during outcome 1 will be correlated with the clinical scores and will be statistically tested for reliability and robustness. The effect sizes of these statistical and correlation matrices will be used to evaluate the feasibility of the signatures as reliable biomarkers for motor neuron conditions like ALS.
Non-invasive recording of the SC functional neuro-electric activityBaselineUnderstanding the role of spinal cord (SC) in neuromuscular physiology (in both impaired and healthy individuals) and will also assist in discovering biomarkers in Brain-SC Peripheral connections. This is a perspective outcome that will be future based upon the inferences gained by the first two outcomes.

Countries

Ireland

Contacts

Primary ContactOrla Hardiman, BSc MB BCh BAO MD FRCPI FAAN
hardimao@tcd.ie+353 1 896 4497
Backup ContactPrabhav Mehra, B.E. MSc.
mehrap@tcd.ie+353 0894781347

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026